<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03826524</url>
  </required_header>
  <id_info>
    <org_study_id>EpiDOSE Protocol Version 2.0</org_study_id>
    <nct_id>NCT03826524</nct_id>
  </id_info>
  <brief_title>Epinephrine Dose: Optimal Versus Standard Evaluation Trial</brief_title>
  <acronym>EpiDOSE</acronym>
  <official_title>CanROC Epinephrine Dose: Optimal Versus Standard Evaluation Trial (CanROC EpiDOSE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this randomized controlled trial is to evaluate the effectiveness of a low&#xD;
      cumulative dose of epinephrine compared to a standard cumulative dose of epinephrine during&#xD;
      resuscitation from ventricular fibrillation (VF) or ventricular tachycardia (VT) in adult&#xD;
      out-of-hospital cardiac arrest (OHCA) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a prospective, multicentre, single-blinded randomized controlled&#xD;
      trial (RCT) where eligible OHCA patients are randomized to receive a low cumulative dose of&#xD;
      epinephrine (low dose epinephrine, up to 2mg total) or a standard cumulative dose of&#xD;
      epinephrine (standard dose epinephrine, up to 6mg total) in a 1:1 fashion.&#xD;
&#xD;
      Eligible OHCA patients will be treated by emergency medical service (EMS) providers who will&#xD;
      initiate cardiopulmonary resuscitation (CPR) and the delivery of defibrillation shocks per&#xD;
      EMS treatment protocols. After one defibrillation and when feasible, EMS providers will&#xD;
      establish peripheral intravenous (IV) access, and patients will be randomly allocated to 1 of&#xD;
      the 2 study arms. Subsequent study drug doses will be administered every 3-5 minutes, based&#xD;
      on current guidelines and paramedic protocols, during resuscitation until the first return of&#xD;
      spontaneous circulation (ROSC) is achieved or if resuscitation has been terminated by the&#xD;
      base hospital physician. Other medications (e.g. antiarrhythmics, magnesium, beta blockers)&#xD;
      and interventions (e.g. intubation) may be interposed as required. Follow-up will take place&#xD;
      using a combination of administrative databases (e.g. the Discharge Abstract Database and the&#xD;
      National Ambulatory Care Reporting System) and telephone interviews.&#xD;
&#xD;
      This RCT will evaluate a fundamental change in the treatment of OHCA. The investigators&#xD;
      hypothesize that a low cumulative dose of epinephrine will improve patient survival to&#xD;
      hospital discharge compared to a standard cumulative dose of epinephrine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival to hospital discharge</measure>
    <time_frame>Through study completion (up to 5 years)</time_frame>
    <description>Individuals discharged alive from hospital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Return of spontaneous circulation in out-of-hospital setting</measure>
    <time_frame>Through study completion (up to 5 years)</time_frame>
    <description>Return of spontaneous circulation in the field</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to emergency department arrival</measure>
    <time_frame>Through study completion (up to 5 years)</time_frame>
    <description>Individuals alive upon arrival to a hospital emergency department</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to admission with death prior to discharge</measure>
    <time_frame>Through study completion (up to 5 years)</time_frame>
    <description>Individuals alive upon hospital admission who die in-hospital before being discharged</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to discharge outside of a long-term healthcare facility e.g. nursing home</measure>
    <time_frame>Through study completion (up to 5 years)</time_frame>
    <description>Individuals discharged alive from hospital to a care facility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) score</measure>
    <time_frame>12+/-3 months</time_frame>
    <description>Assessment of neurological function, scores range from 0 to 6 where higher scores indicate worse neurological function (0=no symptoms, 6=dead)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Utility Index-3 (HUI-3) score</measure>
    <time_frame>12+/-3 months</time_frame>
    <description>Assessment of quality of life, scores range from -0.36 to 1 where higher scores indicate better quality life (negative scores=a state worse than being dead, 0=dead, 1=perfect health)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale score</measure>
    <time_frame>12+/-3 months</time_frame>
    <description>Assessment of quality of life, scores range from 0 to 21 where higher scores indicate more anxiety/depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>Through study completion (up to 5 years)</time_frame>
    <description>Length of time an individual remained in-hospital (length in days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in critical care unit</measure>
    <time_frame>Through study completion (up to 5 years)</time_frame>
    <description>Length of time an individual remained in a crucial care unit (length in days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival post-arrest</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Survival following hospital discharge, up to 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent cardiac arrest(s)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Number of cardiac arrests following the index arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICD implant post-arrest</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Whether an implantable cardioverter defibrillator was implanted post-arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular re-hospitalization(s)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Number of cardiovascular re-hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause re-hospitalizations(s)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Number of re-hospitalizations for any reason</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3790</enrollment>
  <condition>Cardiac Arrest, Out-Of-Hospital</condition>
  <condition>Sudden Cardiac Arrest</condition>
  <condition>Ventricular Fibrillation</condition>
  <condition>Ventricular Tachycardia-Pulseless</condition>
  <arm_group>
    <arm_group_label>Low Dose Epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epinephrine up to 2mg total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epinephrine up to 6mg total</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Epinephrine 1mg 1:10000 (10cc) per dose</description>
    <arm_group_label>Low Dose Epinephrine</arm_group_label>
    <arm_group_label>Standard Dose Epinephrine</arm_group_label>
    <other_name>Adrenaline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Out-of-hospital cardiac arrest treated by paramedics&#xD;
&#xD;
          2. Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis&#xD;
             administered or witnessed by EMS (paramedic or fire)&#xD;
&#xD;
          3. Established intravenous vascular access&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or apparent age &lt;18 years&#xD;
&#xD;
          2. Initial recorded cardiac rhythm of pulseless electrical activity or asystole&#xD;
&#xD;
          3. Cardiac arrest due to an obvious non-cardiac primary cause (e.g. blunt or penetrating&#xD;
             trauma, exsanguination, burns, drug overdose, drowning, anaphylaxis, sudden&#xD;
             asphyxiation, etc.)&#xD;
&#xD;
          4. Prior receipt of non-study kit intravenous or intramuscular epinephrine during&#xD;
             resuscitation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Dorian, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Lin, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unity Health Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theresa Aves, MSc</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>46787</phone_ext>
    <email>theresa.aves@unityhealth.to</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Unity Health Toronto</investigator_affiliation>
    <investigator_full_name>Paul Dorian</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>out-of-hospital cardiac arrest</keyword>
  <keyword>sudden cardiac arrest</keyword>
  <keyword>epinephrine</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

